N-Propyliden-ethylamin | 18328-91-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Propyliden-ethylamin
• 英文别名: Propionaldehyde ethylimine；N-ethylpropan-1-imine
• CAS: 18328-91-1
• 化学式: C₅H₁₁N
• 分子量: 85.149
• InChiKey: ZVYCPFCNAXPUFP-UHFFFAOYSA-N

物化性质

• 沸点：
  110.2±13.0 °C(Predicted)
• 密度：
  0.73±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  6
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-Propyliden-ethylamin 在 乙醇 、 铂 作用下， 生成 N-乙基正丙胺
  参考文献：
  名称：

  Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria

  摘要：

  The aim of this study is to compare the efficacy of an angiotensin-converting enzyme inhibitor with a dihydropyridine calcium channel blocker in preventing progression to macroalbuminuria and/or a decline in renal function in normotensive patients with type 1 diabetes and microalbuminuria. Forty-two patients were randomized to treatment with either perindopril, slow-release nifedipine, or placebo. In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm Hg. Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months). Patients were studied every 3 months and at the end of the treatment period; those who remained normotensive discontinued therapy and were followed up for an additional 3 months. Baseline geometric mean albumin excretion rates (AERs) were as follows: perindopril, 66 mug/min; nifedipine, 59 mug/min; and placebo, 66 mug/min. During the first 3 years, 7 of the perindopril-treated but none of the placebo or nifedipine-treated patients reverted to normoalbuminuria (P < 0.01). Median AERs at 3 years of treatment in each group were 23 g/min for perindopril, 122 mug/min for nifedipine, and 112 mug/min for placebo patients (P < 0.01). in patients with more than 3 years' follow-up, median AERs decreased by 45% in the first year and then stabilized in the perindopril group, but increased by 17.6% in the nifedipine group and 27.6% in the placebo group (P < 0.03) in the first year, then increased progressively. In these same patients, there was a significant decline in glomerular filtration rate in the nifedipine group (-7.8 +/- 1.8 mL/min/1.73 m(2)/y), but not in the other two groups (perindopril, -1.0 +/- 1.2 mL/min/1.73 m(2)/y; placebo, -1.3 +/- 1.1 mL/min/1.73 m(2)/y; P = 0.004). At the end or the study, cessation of treatment for 3 months was associated with a doubling of AERs in the perindopril-treated group, but no change in the other two groups (P < 0.001). In conclusion, long-term perindopril therapy is more effective than nifedipine or placebo in delaying the progression of diabetic nephropathy and reducing AER to the normoalbuminuric range (<20 mug/min) in normotensive patients with type I diabetes and microalbuminuria. (C) 2000 by the National Kidney Foundation, Inc.

  DOI：

  10.1016/s0272-6386(05)80003-4
• 作为产物：
  描述：

  乙胺 、 丙醛 生成 N-Propyliden-ethylamin
  参考文献：
  名称：

  Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria

  摘要：

  The aim of this study is to compare the efficacy of an angiotensin-converting enzyme inhibitor with a dihydropyridine calcium channel blocker in preventing progression to macroalbuminuria and/or a decline in renal function in normotensive patients with type 1 diabetes and microalbuminuria. Forty-two patients were randomized to treatment with either perindopril, slow-release nifedipine, or placebo. In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm Hg. Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months). Patients were studied every 3 months and at the end of the treatment period; those who remained normotensive discontinued therapy and were followed up for an additional 3 months. Baseline geometric mean albumin excretion rates (AERs) were as follows: perindopril, 66 mug/min; nifedipine, 59 mug/min; and placebo, 66 mug/min. During the first 3 years, 7 of the perindopril-treated but none of the placebo or nifedipine-treated patients reverted to normoalbuminuria (P < 0.01). Median AERs at 3 years of treatment in each group were 23 g/min for perindopril, 122 mug/min for nifedipine, and 112 mug/min for placebo patients (P < 0.01). in patients with more than 3 years' follow-up, median AERs decreased by 45% in the first year and then stabilized in the perindopril group, but increased by 17.6% in the nifedipine group and 27.6% in the placebo group (P < 0.03) in the first year, then increased progressively. In these same patients, there was a significant decline in glomerular filtration rate in the nifedipine group (-7.8 +/- 1.8 mL/min/1.73 m(2)/y), but not in the other two groups (perindopril, -1.0 +/- 1.2 mL/min/1.73 m(2)/y; placebo, -1.3 +/- 1.1 mL/min/1.73 m(2)/y; P = 0.004). At the end or the study, cessation of treatment for 3 months was associated with a doubling of AERs in the perindopril-treated group, but no change in the other two groups (P < 0.001). In conclusion, long-term perindopril therapy is more effective than nifedipine or placebo in delaying the progression of diabetic nephropathy and reducing AER to the normoalbuminuric range (<20 mug/min) in normotensive patients with type I diabetes and microalbuminuria. (C) 2000 by the National Kidney Foundation, Inc.

  DOI：

  10.1016/s0272-6386(05)80003-4

文献信息

• The Synthesis of Esters of Substituted Amino Phosphonic Acids^1a
  作者：Ellis K. Fields

  DOI：10.1021/ja01126a054

  日期：1952.3
• Kirrmann; Laurent, Bulletin de la Societe Chimique de France, 1939, vol. <5> 6, p. 1657,1662
  作者：Kirrmann、Laurent

  DOI：——

  日期：——
• Rau; Narayanaswamy, Zeitschrift für physikalische Chemie. Abteilung B, Chemie der Elementarprozesse, Aufbau der Materie, 1934, vol. 26, p. 23,36
  作者：Rau、Narayanaswamy

  DOI：——

  日期：——